Subscribe to the BioNews newsletter for free

Advanced Search

Search for

Like the Progress Educational Trust on Facebook



Summit agrees genome editing to proceed, with caution

07 December 2015

By Dr Jane Currie

Appeared in BioNews 831

An international summit has agreed conditions under which human genome editing, using techniques like CRISPR, should proceed.

The International Summit on Gene Editing, held in Washington, was a collaboration between the US National Academies of Sciences and Medicine, the UK Royal Society, and the Chinese Academy of Sciences. The Summit Organising Committee called the meeting in response to rapidly increasing research using genome-editing techniques, such as CRISPR.

CRISPR allows quicker, cheaper and more accurate genome editing than previously possible, but its sudden prominence has raised important ethical and societal questions.

'The overriding question is when, if ever, we will want to use gene editing to change human inheritance,' said Professor David Baltimore, leader of the Summit Organising Committee, at the opening of the summit.

Scientists, clinicians, patients and ethicists spent three days discussing the pros and cons of genome editing, which led to an agreed statement from the Organising Committee about how to go forward.

First, they said that basic and preclinical research 'should proceed', particularly to improve genome-editing technology or to understand its benefits and risks. However, they emphasised that any early human embryos or germline cells that have been edited should not be used to establish a pregnancy.

Second, they support the editing of somatic cells (that is, cells that cannot be transmitted to the next generation). They explained that such research may help treat genetic conditions and would be regulated using the existing clinical research frameworks in place for gene therapy.

Third, they said that the clinical use of germline cell editing, which could potentially be used to avoid severe inherited diseases or 'enhance' human capabilities, would currently be 'irresponsible'. They added that the ethical and societal issues of germline editing have not been sufficiently explored, and the risk of possible harm to future generations is too great.

Finally, they recommended setting up an international forum to lead on further work in this area: 'The international community should strive to establish norms concerning acceptable uses of human germline editing and to harmonize regulations, in order to discourage unacceptable activities while advancing human health and welfare.'

However, not all scientists are satisfied with the outcome of the summit. 'I'm disappointed that the organisers did not propose at least a temporary moratorium on germline human genetic modification,' Dr Paul Knoepfler, a cell biologist at the University of California, told the Guardian.

'It's not clear to me what the downside of a temporary moratorium would have been. Several of the organisers clearly and in some cases strongly advocated for a "pause" in germline editing in the last few months. What changed?'

Before the summit, CRISPR pioneer Professor Jennifer Doudna, another member of the Organising Committee, wrote in Nature:

'In my view, a complete ban might prevent research that could lead to future therapies, and it is also impractical given the widespread accessibility and ease of use of CRISPR/Cas9. Instead, solid agreement on an appropriate middle ground is desirable.

'In addition, future discussions that build on this December's meeting should address other potentially harmful applications of genome editing in non-human systems, such as the alteration of insect DNA to "drive" certain genes into a population.'

The Progress Educational Trust's public conference 'From Three-Person IVF to Genome Editing: The Science and Ethics of Engineering the Embryo' is taking place in central London on Wednesday 9 December 2015. Find out more here.

Scientists improve CRISPR accuracy

Although CRISPR/Cas9 has been a major step forward in the accuracy of genome editing, it still frequently leads to modifications at sites in the genome other than that intended. This is a major cause for concern regarding potential future applications in humans.

The Broad Institute team involved in developing CRISPR/Cas9 have now modified the genome-editing technique to significantly reduce the numbers of off-target effects. Professor Feng Zhang and colleagues report in Science that modifying three amino acids in Cas9, the enzyme that 'cuts'  DNA during modification, reduced off-target effects to undetectable levels.

The modified protein, which the researchers have named 'enhanced' S. pyogenes Cas9 (eSpCas9), is now being made available to researchers worldwide.

'Many of the safety concerns [about genome editing] are related to off-target effects,' said Professor Zhang. 'We hope the development of eSpCas9 will help address some of those concerns, but we certainly don't see this as a magic bullet. The field is advancing at a rapid pace, and there is still a lot to learn before we can consider applying this technology for clinical use.'

STAT | 02 December 2015
Science News | 03 December 2015
Scientific American | 03 December 2015
The National Academies of Science, Engineering & Medicine | 03 December 2015
Nature News | 02 December 2015
New York Times | 03 December 2015
The Guardian | 03 December 2015


06 February 2017 - by Rachel Siden 
The American College of Medical Genetics and Genomics has published a statement recommending caution over the clinical application of genome editing...
03 October 2016 - by Rachel Siden 
Use of genome editing in human reproduction requires 'urgent ethical scrutiny', according to a report published by the Nuffield Council on Bioethics...
12 September 2016 - by Professor Vardit Ravitsky, Professor Bartha Knoppers, Professor Timothy Caulfield, Professor Rosario Isasi, Erika Kleiderman, and Professor Michael Rudnicki 
Gene editing, in particular CRISPR/Cas9 technology, is sweeping the scientific world and has been receiving ample attention from policymakers worldwide. Policy statements and academic papers regarding responsible ways of moving forward with gene editing have already been published...
11 April 2016 - by Ayala Ochert 
A second team in China report that they have created genetically modified human embryos, in an attempt to make them resistant to HIV, using the genome-editing technique CRISPR/Cas9...
22 February 2016 - by Sarah Pritchard 
Professor Matthew Cobb investigates some of the implications of the groundbreaking CRISPR genome-editing technology in this BBC Radio 4 documentary...

30 November 2015 - by Dr Silvia Camporesi and Dr Lara Marks 
It is important to engage the public in the debate about genome editing as early as possible, and in a way that is as open as possible, to make sure that all possible voices are included...
23 November 2015 - by Dr James Legg 
On 26 October this year the CRISPR/Cas patent wars truly began with the filing of European oppositions against what appears to be the first patent granted in Europe for this revolutionary gene-editing technology....
16 November 2015 - by Ari Haque 
A US biotechnology start-up co-founded by two pioneers of CRISPR technology intends to begin gene editing in humans as part of an experimental treatment to target a rare genetic eye disorder...
12 October 2015 - by Dr Silvia Camporesi and Dr Lara Marks 
The UNESCO International Bioethics Committee has released a statement reaffirming an earlier moratorium called by a group of US scientists on the use of CRISPR/Cas9 in human embryos. We argue that the current framing of the debate in terms of dystopic or imagined futures is too narrow and constrains the boundaries of the debate to germline applications...
05 October 2015 - by Meghna Kataria 
Scientists have identified a new version of the gene-editing technique CRISPR, which could enable greater precision in the editing of genomes, while making its use simpler and more flexible...

Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

- click here to enquire about using this story.

Published by the Progress Educational Trust


Public Conference
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation